Portfolio Lab

Supernus, Inc.

  • Stock
  • Ticker SUPN
  • ISIN US45579U1097
  • Nasdaq

Health care · Pharmaceuticals · USA

$28.61 +0.92%
Close of 20 Nov 2026
Open in backtest

Performance, volatility and drawdowns of Supernus, Inc. since 11/2016, with distributions reinvested and calculated in US dollars. As of 20 Nov 2026.

Performance

SUPNGlobal equities (VT)

$10,000 grew to $17,685. Global equities (VT): $29,042.

Distributions reinvested, before taxes and brokerage costs. Dashed: Global equities (VT) for comparison.

Declines from the peak

Lowest point −93.8% in 04/2019, measured from the peak in 06/2018. It took 90 months to get back to the old peak.

1-year return
+16.1%
5-year return p.a.
+16.6%
10-year return p.a.
+5.9%
Volatility p.a.
57.2%
Largest decline
−93.8%

Financial statements

Amounts in $ millions from filings with the SEC, earnings per share in $; fourth quarter and quarterly cash flow derived from year-to-date figures

Quarter end12/202403/202506/202509/202512/202503/202606/202609/2026
Income statement
Revenue299266302314358317343356
Gross profit250221250230292277294305
Operating income4666724381137160180
EBITDA5169744683139162181
Net income2147184210289122137
Earnings per share0.160.380.140.330.790.690.981.12
Balance sheet
Total assets1,3161,3751,4521,4161,2011,1971,2331,332
Liabilities1,6521,6601,7091,6231,3001,3411,4411,392
Equity-337-285-257-207-98-144-208-60
Cash319372510445195175222305
Long-term debt3153113083042904864870.0
Cash flow
Operating cash flow-1775158-39-221-9.022997
Capital expenditure-16-5.0-17-20-24-20-7.0-14
Free cash flow-3370141-59-245-2922283

Value it:DCF calculatorMultiples calculator

Annual returns

Best year 2025 at +188.7%, weakest 2018 at −75.5%. 5 of 9 full years were positive. * partial year.

Quarterly reports

Filing date with the SEC and earnings per share of the quarter

DayEarnings per share
29 Oct 2026$1.12
3 Aug 2026$0.98
30 Apr 2026$0.69
26 Feb 2026$0.79
30 Oct 2025$0.33
31 Jul 2025$0.14
1 May 2025$0.38
3 Mar 2025$0.16

Key metrics

Metrics of 15 Nov 2026; P/E, P/B, P/S, market cap and dividend yield at the last close.

Valuation

Market cap
€3.1bn
Market cap in trading currency
$3.38bn
Enterprise value
$3.56bn
P/E
8.0
P/S
2.46
P/B
–
EV/Sales
2.59
EV/EBITDA
6.3
Earnings yield
12.5%
FCF yield
0.9%

Results (last four quarters)

Revenue
$1.37bn
Gross profit
$1.17bn
EBITDA
$565m
Net income
$450m
Earnings per share
$3.58
Revenue per share
$11.64
Revenue growth
+13.4%
Earnings growth
+226.2%

Profitability

Gross margin
85.0%
Operating margin
40.6%
Net margin
32.8%
Return on equity
–
Return on assets
33.8%

Balance sheet and cash flow

Cash
$305m
Cash per share
$2.58
Financial debt
$488m
Debt/equity %
–
Current ratio
0.61
Book value per share
−$0.51
Operating cash flow
$96.0m
Free cash flow
$31.0m

Dividend

Dividend yield
28.42%
Dividend (12 months)
$8.13
Yield (12 months)
28.42%
Payout ratio
227%
Ex-dividend date
3 Nov 2026

Shares and trading

Shares outstanding
118m
Volume
2.83m
Avg. volume 3 months
2.72m
Relative volume
1.0

Price and technicals

Price
$28.61
1 day
+0.9%
52-week high
$41.83
52-week low
$26.16
Distance to 52-week high
−31.6%
Distance to 52-week low
+9.4%
Distance to 50-day line
−14.2%
Distance to 200-day line
−18.9%
RSI (14)
38
Volatility 1M
96.6%

Performance

1 week
−3.7%
1 month
−19.0%
3 months
−20.9%
6 months
−23.8%
YTD
−20.3%
1 year
−12.2%

Dates

Fiscal year end
31 Dec 2025
Most recent quarter
30 Sep 2026

Frequently asked questions

How has SUPN performed since 11/2016?

$10,000 grew to $17,685 by 20 Nov 2026, which is +5.9% per year. Distributions are reinvested; taxes and brokerage costs are not deducted.

How volatile is SUPN?

Volatility was 57.2% per year, measured on monthly returns. The largest decline from a peak was −93.8%, with the low in 04/2019.

How does SUPN compare with a broad equity ETF?

Over the same period Global equities (VT) returned +11.3% per year at 15.1% volatility, SUPN returned +5.9% at 57.2%. The correlation of monthly returns was 0.15; 1 would mean they moved in lockstep.

Which currency are the figures in?

In US dollars, the currency of the US listing.

Not investment advice. Metrics and financial statements calculated from the company's mandatory filings with the SEC, without guarantee; amounts in US dollars.

Reference data of securities: source ESMA (FIRDS reference data) and SEC (EDGAR).

Not investment advice: results in Portfolio Lab are model calculations based on historical data and your inputs. Past performance is not a reliable indicator of future results.

Supernus, Inc. (SUPN): Return and risk | Portfolio Lab